Diabetes Care Intelligence Center 2012-2023 – A 2019 Database with Forecast Coverage on Value, Volume Sales, and Price & Price Per-Capita Expenditure – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetes
Care Intelligence Center 2012-2023” report has been added to ResearchAndMarkets.com’s
offering.

The Diabetes Care Intelligence Center (IC) is a global
intelligence database on diabetes drugs & devices, which offers data on
25 major countries.

It covers 13 years of comparable data, including 5-year forecasts
incorporating value, volume sales, and price and price per-capita
expenditure. The Intelligence Centre enhances your understanding of the
diabetes drugs industry, along with economic factors impacting diabetes
drug usage, such as diabetes population, Type 1 and Type 2 Diabetic
population, and obesity, which provide you with actionable business
insights.

Market Scope

• Diabetes drugs & devices market data, volume and value analytics with
  growth trends (2012-2023)
• Branded & generic drugs and devices’ sales data from 2012-2023
• Segment, sub-segment & company devices’ sales data from 2012-2023
• Additional information includes – diabetic population levels, diabetes
  prevalence, Diabetes Type 1 population, Diabetes Type 2 population,
  and per-capita expenditure.

The Diabetes Care Intelligence Center provides exhaustive
coverage (countries covered account for more than 80% of the overall
spending on diabetes). Covering and tracking of over 18,000 data points
of the diabetes drugs industry, which covers various categories,
segments, Active Pharmaceutical Ingredients (APIs), and brands. It also
covers more than 8,000 data points of the diabetes care device market,
which encompass various categories, segments, sub-segments and company
share analysis.

Market Overview

The global diabetes care market is expected to grow because of the
growing diabetes population levels and increasing diabetes expenditure
in established, as well as pharma emerging countries.

Global Rise in Diabetic Population

• There has been a tremendous increase in the global diabetic population
  levels over the past decade. Several reports and surveys documented a
  drastic increase in the diabetic population levels, based on the
  changing lifestyles and habits.
• Extensive urbanization in various parts of the globe is considered to
  be the primary cause of obesity, health deterioration, physical
  inactivity, etc. Owing to these factors the prevalence of Type 2
  Diabetes mellitus (T2DM) has increased significantly.
• It is estimated that out of the total 415 million people suffering
  from diabetes worldwide, 46% of this demographic is those with
  undiagnosed diabetes.
• The growing diabetic population levels act as a driver for insulin
  monitoring devices, such as glucometers, CGMs, etc. In developed
  countries, close to 90% of Type 1 Diabetic patients use glucometers.
  It is expected that during the forecast period close to 50% of Type 2
  Diabetic patients will use a glucometer.

The United States Leads the Diabetes Drugs & Devices Market

• In 2017, the US diabetes drugs market held the largest market share in
  North America, due to the presence of a high-quality healthcare system
  and increasing prevalence of diabetes in the region.
• In the Asia-Pacific region, China and India have been identified as
  potential emerging markets, due to the rising diabetic population
  levels.

Diabetes Drug Categories

• Insulin
• Basal Insulin or Long-acting Insulin
• Bolus Insulin or Fast-acting Insulin
• Pre-mixed Insulin or Combination Insulin
• Traditional Human Insulins
• Traditional Human Insulin Biosimilars
• Insulin Glargine Biosimilars
• Non-Insulin Injectable
• GLP-1 Agonist Market
• Amylin Analogue
• Oral Anti-diabetics Drugs
• Dopamine-D2 Receptor Agonist
• Meglitinide
• Alpha-Glucosidase Inhibitors
• SGLT2 Inhibitors
• Biguanides
• Sulfonylureas
• DPP-4 Inhibitors
• Combination Drugs
• Insulin Combinations
• Oral Combinations
• Diabetes Device Categories
• Management Devices
• Insulin-delivery Devices
• Insulin Syringes
• Cartridges in Reusable Pens
• Disposable Pens
• Jet Injectors
• Insulin Pump
• Insulin Pump Devices
• Insulin Pump Reservoirs
• Infusion Sets
• Monitoring Devices
• Self-monitoring Blood Glucose Devices (SMBG)

By Component

• Glucometer Devices
• Test Strips
• Lancets
• By End-user
• Hospital
• Glucometer Devices
• Test Strips
• Lancets
• Personal
• Glucometer Devices
• Test Strips
• Lancets
• Continuous Glucose Monitoring Devices (CGM)
• CGM durables (Receivers and Transmitters)
• Sensors

Reasons to Purchase this Dashboard

• More Granular: Covers more categories, segments and brands’
  information at country and global levels compared to other market
  intelligence providers
• Analyzing the outlook of the market with recent market data,
  historical data and market forecast
• Ease of Comparability: Analytics are based on a standardized
  definition across the globe to facilitate better comparability of
  market data
• View the market in different ways among categories and geography to
  understand where actual opportunities lie
• Market segmentation including quantitative research, incorporating the
  impact of economic and non-economic aspects
• Regional- and country-level data integrating the demand and supply
  forces which are influencing the growth of the market
• Market value (in USD million) and volume data for each segment and
  sub-segment
• Understanding of the market based on value and volume changes, intra
  category competition.
• Dedicated analyst support for research queries and training
• Continuous yearly amendment of the database with significant changes
  updated based on scenarios

Countries Covered

• United States
• Canada
• France
• Germany
• Italy
• Spain
• United Kingdom
• Russia
• Mexico
• Brazil
• Japan
• South Korea
• China
• India
• Australia
• Vietnam
• Malaysia
• Indonesia
• Philippines
• Thailand
• Saudi Arabia
• Iran
• Egypt
• Oman
• South Africa

List of Topics Covered

1. Introduction

1.1 Key Deliverables of the Study

1.2 Market Definition

2. Research Approach and Methodology

2.1 Introduction

2.2 Research Designs

2.3 Study Phases

2.3.1 Internal Sources Evaluation

2.3.2 Research Process

2.3.3 Modeling & Triangulation

2.3.4 Data Finalization

2.3.5 Expert Validation

3. Market Segmentation

3.1 By Drug

3.1.1 Oral Anti-diabetic drugs

3.1.2 Insulin

3.1.3 Non-Insulin Injectable Drugs

3.1.4 Combination Drugs

3.2 By Device

3.2.1 Monitoring Devices

3.2.2 Management Devices

3.3 Geography

3.3.1 North America

3.3.2 Europe

3.3.3 Latin America

3.3.4 Asia-Pacific

3.3.5 Middle East & Africa

4. Market Indicators

4.1 Type-1 Diabetes Population (2012-2023)

4.2 Type-2 Diabetes Population (2012-2023)

5. Company Share Analysis

Companies Mentioned

• Abbott Diabetes Care
• Acon
• Agamatrix Inc.
• Arkray
• Ascensia Diabetes Care
• Astellas
• AstraZeneca
• Bionime Corporation
• Boehringer Ingelheim
• Bristol Myers Squibb
• Dexcom
• Eli Lilly
• Janssen Pharmaceuticals
• Johnson & Johnson
• Medisana
• Medtronic
• Merck and Co.
• Novartis
• Novo Nordisk
• Pfizer
• Roche
• Rossmax
• Sanofi
• Takeda
• Trivida

For more information about this report visit https://www.researchandmarkets.com/research/t5h36h/diabetes_care?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrinology